Aim Gemcitabine-based chemotherapy regimens remain the standard first-line treatment for
advanced biliary tract cancers (BTCs) patients with no second-line treatments established …

Biliary tract carcinoma (BTC) has a poor prognosis and is increasing in incidence. Although
surgery, chemotherapy and other treatment modalities have improved, surgery remains the …

Background The majority of advanced biliary tract cancer (ABTC) patients will progress after
gemcitabine and cisplatin (GP) doublet therapy, while the standard second-line regimen has …

Background: A systematic review was conducted to understand clinical, economic and
health-related quality-of-life outcomes in second-line biliary tract cancer. Materials & …

Background Cholangiocarcinoma (CCA) is the second most frequent primary liver tumor and
defined as the heterogeneous group of tumors derived from cells in the biliary tree. Methods …

Background Biliary cancers are aggressive carcinomas frequently diagnosed at an
advanced stage. Palliative combination systemic therapy provides survival benefits in the …

Purpose The survival benefit of first-line chemotherapy (CT1) for biliary tract cancer (BTC) is
now established but the role of second-line chemotherapy (CT2) has not been fully …

Simple Summary Cholangiocarcinoma are mostly diagnosed at a late stage and early
recurrence is also very common with 5-year survival rates of< 5% in unresectable, and 33 …

Systemic treatment is important for patients with unresectable biliary tract cancer. Various
treatments using cytotoxic agents, molecular-targeted agents, and immunotherapy have …

Einleitung: Die malignen biliären Tumoren (mBT) sind eine heterogene Gruppe seltener
Tumorerkrankungen der Gallenblase und der Gallengänge. Die mBT werden häufig in …